Skip to content

Total debt at other companies

HRO
HarrowHROW
$308.58M-32.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$36.83M+59.4%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$79.46M+4.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.42M-42.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$75.03M+37.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $55.99M.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's total debt?
Kodiak Sciences Inc (KOD) reported total debt of $55.99M in Q1 2026.
How has Kodiak Sciences Inc's total debt changed year-over-year?
Kodiak Sciences Inc's total debt decreased by 17.2% year-over-year, from $67.64M to $55.99M.
What is the long-term trend for Kodiak Sciences Inc's total debt?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's total debt has grown at a -5.2% compound annual growth rate (CAGR), from $77.4M to $59.18M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.